Kidney ScarringMARSNCT04625140
Detection of Renal Fibrosis and Prediction of Kidney Function Decline
An observational study of Kidney Scarring, run by University Hospital, Akershus at 1 site in Norway.
Trial summary
This study will investigate the ability of renal MRI to detect fibrosis, how this correlates to renal function and how well renal MRI biomarkers can predict decline in kidney function over time. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Scarring
- How many people
- 72 participants
- Where
- 1 siteNorway
- Study dates
- 1 Feb 2021to 30 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients scheduled for a renal biopsy will have one or more of the following conditions; Reduced kidney function as determined by eGFR (acute or chronic), hematuria, proteinuria, nephrotic syndrome or nephrittic syndrome. Patients with increased risk of complications from a biopsy will likely be excluded (single kidney, bleeding disorder, double anti-platelet therapy, anticoagulant therapy).
Who may be able to join
- Patients over 18 years of age, who is scheduled for a kidney biopsy for diagnostic purposes at the Department of Nephrology, Akershus University Hospital will be invited to participate in the study.
Who cannot join
- Patients who are not able to understand information in order to give informed consent.
- Patients with claustrophobia.
- Patients with implanted metal devices which are not compatible with MRI.
Trial locations and contacts
1 site in 1 country.
Norway1 site, 1 recruiting
- Recruiting
Akershus University Hospital
Oslo, Lørenskog, 1478
About this study
Official title: Detection of Renal Fibrosis and Prediction of Kidney Function Decline: The Role of MRI and Markers of Accelerated Renal Ageing (MARS)
This study will investigate the ability of renal MRI to detect fibrosis, how this correlates to renal function and how well renal MRI biomarkers can predict decline in kidney function over time. We will also assess the correlation of renal MRI and kidney function to markers of renal ageing in blood, urine and tissue samples.
Read the detailed description
Chronic kidney disease (CKD) is an increasing health concern worldwide, with an estimated prevalence of 11% in the Norwegian population. Progression of CKD and development of end-stage kidney disease is closely related to the extent and progression of renal fibrosis. Traditionally the assessment of renal fibrosis is made by renal biopsy, which in addition to diagnostics also evaluates the degree of renal fibrosis.
However, the evaluation of fibrosis from a renal biopsy is limited by the risk of complications. Due to its invasive nature, clinicians often reserve a biopsy for situations where the anticipated yield will have therapeutic value. This means the fibrotic burden is often not assessed, and information on scar burden and kidney-prognosis is lost. Furthermore, we know that fibrosis may be unequally distributed throughout the kidney. Since a biopsy only samples a small portion of kidney tissue, it is inherently susceptible to sampling bias.
In contrast, Magnetic Resonance Imaging (MRI) techniques can assess whole organ fibrotic burden. Since it is a non-invasive procedure, MRI can evaluate renal fibrosis in patients not eligible for renal biopsy. Moreover, it can be performed at several time-points for temporal renal fibrosis assessments. Recent developments in MRI techniques have made it possible to assess renal fibrosis with MRI. These techniques rely on the different biological properties of fibrotic and non-fibrotic tissues, including reduced microcirculation, restriction of water motion and reduced oxygenation. From several MRI biomarkers currently available, five show particular promise in quantifying degree of renal fibrosis: Diffusion weighted MRI, T1-mapping and T2-mapping, T1-rho and arterial-spin labelling. A recently developed MRI-patch which combines these five techniques, makes it possible to perform a MRI-scan with simultaneous measurements whilst not prolonging examination time for the patient. We hypothesize that combining these MRI-techniques will give additional information, and thus provide a better correlation to histological-assessed fibrosis than any technique alone.
Markers of renal ageing may also predict development of renal fibrosis as accelerated renal ageing trough p16INK4a pathway activation, leading to cellular senescence, is involved in the development of renal fibrosis in CKD. Senescent cells are characterized by irreversible growth arrest and express a pro-inflammatory and pro-fibrotic senescent-associated secretory phenotype (SASP). This biochemical foot print can be detected by immunohistochemistry. We aim to assess the correlation between degree of renal fibrosis and markers of renal ageing, as well as to what extent decline in kidney function can be predicted by change in markers of renal ageing.
This study will be one of the first to evaluate correlation between multiparametric MRI and morphometric estimates of renal fibrosis. We will study whether activation of pathways involved in renal ageing are associated with progressive renal fibrosis and deterioration of renal function. Finally, we will evaluate the utility of temporal measurements of renal fibrosis for prediction of renal function deterioration with a non-invasive method.
- Conditions
- Kidney Scarring
- Keywords
- MRI
- Medical subject headings
- Glomerulonephritis
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation of renal fibrosis
To assess correlations between degree of renal fibrosis determined by a multiparametric MRI protocol and gold-standard morphometric evaluation of renal fibrosis in renal biopsies at baseline (time of scheduled renal biopsy) and after two years (final visit).
Measured: 5 years
Secondary outcomes (3)
Correlation between renal fibrosis and kidney function
To assess correlations between degree of renal fibrosis (determined by MRI and by morphometry) and renal function (measured glomerular filtration rate by iohexol clearance) and markers of renal ageing at baseline and at the final visit.
Measured: 5 years
Prediction of kidney function decline
To evaluate to what extent change in renal function between baseline and the final visit is predicted by change in markers of renal ageing and degree of renal fibrosis (determined by MRI and by morphometry).
Measured: 5 years
Change in renal function and degree of fibrosis stratifies by disease and use of medication
To evaluate associations between change in degree of renal fibrosis, renal function and markers of renal ageing stratified by renal disease and use of selected medication (immunosuppressive drugs and antihypertensive drugs).
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2020
- Study start1 Feb 2021
- Primary completion24 Nov 2023 (estimated)
- Study completion30 Aug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney ScarringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Akershus
- Sponsor type
- University, hospital or other
- Collaborators
- Aarhus University Hospital
- Responsible party
- Principal investigator, Christian Aalborg, University Hospital, Akershus
- Investigators
- My Hanna Sofia Svensson, Professor, Study director, University Hospital, Akershus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04625140
- Sponsor's protocol ID
- 2020_161
- Acronym
- MARS
- Status last verified
- Feb 2023
- First submitted
- 6 Nov 2020
- Last updated
- 6 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Detection of Renal Fibrosis and Prediction of Kidney Function Decline: The Role of MRI and Markers of Accelerated Renal Ageing (MARS)
- ClinicalTrials.gov ID
- NCT04625140
- Acronym / sponsor ID
- MARS / 2020_161
- Conditions
- Kidney Scarring
- Keywords
- MRI
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- University Hospital, AkershusUniversity, hospital or other
- Collaborators
- Aarhus University Hospital
- Study start
- 1 Feb 2021 (actual)
- Primary completion
- 24 Nov 2023 (estimated)
- Study completion
- 30 Aug 2025 (estimated)
- First posted
- 12 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigate the ability of renal MRI to detect fibrosis, how this correlates to renal function and how well renal MRI biomarkers can predict decline in kidney function over time. We will also assess the correlation of renal MRI and kidney function to markers of renal ageing in blood, urine and tissue samples.
Detailed description
Chronic kidney disease (CKD) is an increasing health concern worldwide, with an estimated prevalence of 11% in the Norwegian population. Progression of CKD and development of end-stage kidney disease is closely related to the extent and progression of renal fibrosis. Traditionally the assessment of renal fibrosis is made by renal biopsy, which in addition to diagnostics also evaluates the degree of renal fibrosis.
However, the evaluation of fibrosis from a renal biopsy is limited by the risk of complications. Due to its invasive nature, clinicians often reserve a biopsy for situations where the anticipated yield will have therapeutic value. This means the fibrotic burden is often not assessed, and information on scar burden and kidney-prognosis is lost. Furthermore, we know that fibrosis may be unequally distributed throughout the kidney. Since a biopsy only samples a small portion of kidney tissue, it is inherently susceptible to sampling bias.
In contrast, Magnetic Resonance Imaging (MRI) techniques can assess whole organ fibrotic burden. Since it is a non-invasive procedure, MRI can evaluate renal fibrosis in patients not eligible for renal biopsy. Moreover, it can be performed at several time-points for temporal renal fibrosis assessments. Recent developments in MRI techniques have made it possible to assess renal fibrosis with MRI. These techniques rely on the different biological properties of fibrotic and non-fibrotic tissues, including reduced microcirculation, restriction of water motion and reduced oxygenation. From several MRI biomarkers currently available, five show particular promise in quantifying degree of renal fibrosis: Diffusion weighted MRI, T1-mapping and T2-mapping, T1-rho and arterial-spin labelling. A recently developed MRI-patch which combines these five techniques, makes it possible to perform a MRI-scan with simultaneous measurements whilst not prolonging examination time for the patient. We hypothesize that combining these MRI-techniques will give additional information, and thus provide a better correlation to histological-assessed fibrosis than any technique alone.
Markers of renal ageing may also predict development of renal fibrosis as accelerated renal ageing trough p16INK4a pathway activation, leading to cellular senescence, is involved in the development of renal fibrosis in CKD. Senescent cells are characterized by irreversible growth arrest and express a pro-inflammatory and pro-fibrotic senescent-associated secretory phenotype (SASP). This biochemical foot print can be detected by immunohistochemistry. We aim to assess the correlation between degree of renal fibrosis and markers of renal ageing, as well as to what extent decline in kidney function can be predicted by change in markers of renal ageing.
This study will be one of the first to evaluate correlation between multiparametric MRI and morphometric estimates of renal fibrosis. We will study whether activation of pathways involved in renal ageing are associated with progressive renal fibrosis and deterioration of renal function. Finally, we will evaluate the utility of temporal measurements of renal fibrosis for prediction of renal function deterioration with a non-invasive method.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients scheduled for a renal biopsy will have one or more of the following conditions; Reduced kidney function as determined by eGFR (acute or chronic), hematuria, proteinuria, nephrotic syndrome or nephrittic syndrome. Patients with increased risk of complications from a biopsy will likely be excluded (single kidney, bleeding disorder, double anti-platelet therapy, anticoagulant therapy).
Key inclusion criteria (1 listed)
- Patients over 18 years of age, who is scheduled for a kidney biopsy for diagnostic purposes at the Department of Nephrology, Akershus University Hospital will be invited to participate in the study.
Key exclusion criteria (3 listed)
- Patients who are not able to understand information in order to give informed consent.
- Patients with claustrophobia.
- Patients with implanted metal devices which are not compatible with MRI.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation of renal fibrosis
Time frame: 5 years
To assess correlations between degree of renal fibrosis determined by a multiparametric MRI protocol and gold-standard morphometric evaluation of renal fibrosis in renal biopsies at baseline (time of scheduled renal biopsy) and after two years (final visit).
3 secondary outcomes
Correlation between renal fibrosis and kidney function
Time frame: 5 years
Prediction of kidney function decline
Time frame: 5 years
Change in renal function and degree of fibrosis stratifies by disease and use of medication
Time frame: 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Kidney Scarring
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
RecruitingPhase 4
Dapagliflozin in Active Lupus Nephritis
Lupus Nephritis (LN)
RecruitingPhase 3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Not yet recruitingPhase 3
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
My Hanna Sofia Svensson, Professor study director
University Hospital, Akershus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Scarring, run by University Hospital, Akershus at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christian Aalborg, M.D. (+4793043516, christian.aalborg@ahus.no), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation of renal fibrosis (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2023.